Serum Paraoxonase 1 Activity Status in Patients with Liver Disorders

  title={Serum Paraoxonase 1 Activity Status in Patients with Liver Disorders},
  author={V. Kedage and M. Muttigi and M. S. Shetty and R. Suvarna and Soumya S Rao and C. Joshi and M. Prakash},
  journal={Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association},
  pages={79 - 83}
  • V. Kedage, M. Muttigi, +4 authors M. Prakash
  • Published 2010
  • Medicine
  • Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association
Background/Aim: Paraoxonase 1 (PON1) is an esterase, exclusively synthesized by liver. The present study has two objectives: to determine the PON1 activity status in various disorders associated with hepatocellular damage and to correlate the changes of PON1 activity with the standard liver function and fasting lipid profile tests in these disorders. Patients and Methods: The study groups consisted of 95 patients with liver diseases including acute viral hepatitis (14), cirrhosis with portal… Expand
Paraoxonase Activity in Cirrhotic and Non Alcoholic Steatohepatitis Patients
A positive correlation was seen between PON1 activity and Apo A1 in the two discussed diseases; cirrhosis and non alcoholic steatohepatitis. Expand
Serum Paraoxonase Levels In Patients with Acute Liver Disease
Serum PON is likely to emerge as an additional test of liver function, as it encompasses three different attributes of hepatic function namely, synthetic capacity, detoxication and secretory functions. Expand
Serum lactonase and arylesterase activities in alcoholic hepatitis and hepatitis B
Low PON1 lactonase and AE activity were found in acute viral hepatitis B and in chronic alcoholic hepatitis. Expand
Paraoxonase-1 Serum Concentration and PON1 Gene Polymorphisms: Relationship with Non-Alcoholic Fatty Liver Disease
PON1 serum concentrations were diminished in patients withNAFLD, and the presence of NAFLD was linked with low PON1 concentration, which indicated an important antioxidant role in Paraoxonase-1. Expand
Serum paraoxonase and arylesterase activities in Iranian patients with nonalcoholic fatty liver disease.
  • M. Hashemi, A. Bahari, +4 authors S. Ghavami
  • Chemistry, Medicine
  • Pathophysiology : the official journal of the International Society for Pathophysiology
  • 2012
The results showed that PON1 activity is not a promising biomarker for the evaluation of NAFLD while arylesterase may have, but further studies in larger samples with different ethnic groups are required to validate the findings. Expand
Distribution of Paraoxonase 1 polymorphisms and activities in obese patients
The study revealed that PON1 activities were not influenced by gender and the Q192R genotypes distribution was significantly different in obese patients and the QR genotype influenced greatly the paraoxonase activity. Expand
Alterations in serum paraoxonase-1 activity and lipid profile in chronic alcoholic patients infected with Strongyloides stercoralis.
Investigation of paraoxonase-1 activity, cortisol levels, and the lipid profile in the sera of alcoholic and non-alcoholic Strongyloides stercoralis-infected and uninfected individuals in a sample of 276 individuals attended at the National Health System in Salvador, Bahia, Brazil found an anti-atherogenic pattern. Expand
Paraoxonase 1 genotype-phenotype correlation in patients with metabolic syndrome.
PON1 activities were influenced by all three polymorphisms, regardless of the presence of MS, and no differences for distribution of PON1 -108C>T, -162A>G and -909G>C polymorphisms were found between the two groups. Expand
The Activity and Polymorphism of the PON1 in Patients with Chronic Liver Disease: a Systematic Review and Meta-analysis
Liver diseases are among the ten deadliest diseases in the world. Measuring PON1 is a test to assess the degree of liver disorder. There are several preliminary studies on the rate of PON1 activityExpand
Quantitative proteomic analysis identified paraoxonase 1 as a novel serum biomarker for microvascular invasion in hepatocellular carcinoma.
It is found that serum PON1 was a novel diagnostic biomarker for MVI, a histological sign of micrometastasis in the liver and one of the most powerful prognostic factors in HCC. Expand